VoluMetrix Wins People's Choice Award at American College of Cardiology NIH-NHLBI Company Showcase
CHICAGO, ILLINOIS / ACCESS Newswire / April 10, 2025 / VoluMetrix, an innovative leader in non-invasive cardiovascular monitoring solutions, is proud to announce that it has been awarded the People's Choice Award at the ACC25-NHLBI Company Showcase, held during the American College of Cardiology's Annual Scientific Session in Chicago.American College of Cardiology ACC.25 Innovation Pitch Challenge People's Choice Winner
The prestigious event, hosted on March 29 in the exhibit hall's Future Hub, featured presentations from four cutting-edge companies selected from a competitive pool of companies funded by the National Heart, Lung, and Blood Institute (NHLBI). VoluMetrix was chosen by the ACC Future Hub Task Force to participate in the showcase, which highlights breakthrough technologies with strong commercial potential in cardiovascular care.
As part of the session, each company delivered a pitch followed by Q&A, presenting to an audience of leading cardiologists, key opinion leaders, industry strategics, and private capital investors. Dr. Bret Alvis, VoluMetrix's CMO, captivated the audience with the company's mission to revolutionize heart failure management through its novel, non-invasive hemodynamic monitoring platform.
'We are honored to be recognized by our peers and attendees at ACC25 with the People's Choice Award,' said Kyle Hocking, PhD, CEO of VoluMetrix. 'This recognition affirms the impact our technology can have on improving cardiovascular care and outcomes, and we're excited to continue driving innovation forward.'
The People's Choice Award is a testament to VoluMetrix's ability to connect with clinical and industry stakeholders through its vision, value proposition, and potential to transform the future of cardiac monitoring.
www.volumetrix.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
10 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Yahoo
12 hours ago
- Yahoo
Aker Carbon Capture ASA: Minutes of Extraordinary General Meeting
FORNEBU, Norway, June 6, 2025 /PRNewswire/ -- Reference is made to the stock exchange announcement made by Aker Carbon Capture ASA (Aker Carbon Capture or ACC) on 15 May 2025 regarding the notice of an extraordinary general meeting in connection with the agreement to sell ACC's 20 percent ownership interest in SLB Capturi to Aker ASA (the Transaction) and the proposed dividend to ACC's shareholders as announced on 9 May 2025. The extraordinary general meeting was held today, 6 June 2025. As follows from the attached minutes, all items on the agenda were approved as proposed by the board of directors, including the approval of an audited interim balance sheet of ACC as at 14 May 20205, the distribution of a cash dividend of NOK 2.86 per share, in total approximately NOK 1.7 billion, on the basis of the said interim balance sheet, and the amendment to ACC's purpose as set out in its articles of association. The dividend will be paid on or about 20 June 2025 to ACC's shareholders as of 6 June 2025, as registered in the VPS as of 11 June 2025. The shares will trade exclusive of the right to receive dividend from and including 10 June 2025. For more details about the Transaction, please refer to ACC's stock exchange announcement of 9 May 2025. For further information:Media and Investors: Mats Ektvedt, mobile: +47 41 42 33 28,e-mail: About Aker Carbon Capture ASA Aker Carbon Capture ASA was established as a separate entity in 2020, building on more than 20 years long experience and maturation of the carbon capture technology within Aker. A Joint Venture between SLB and Aker Carbon Capture, SLB Capturi, was established in June 2024 with SLB owning 80% and Aker Carbon Capture ASA indirectly owning 20% through its subsidiary, Aker Carbon Capture AS. On 9 May 2025, Aker Carbon Capture ASA and Aker ASA announced an agreement whereby Aker, through a subsidiary of Aker Capital AS, acquired the 20% ownership interest in SLB Capturi AS held by Aker Carbon Capture ASA's subsidiary Aker Carbon Capture AS. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II. This information was brought to you by Cision The following files are available for download: ACC - Minutes of EGM 6 June 2025 View original content: Sign in to access your portfolio
Indianapolis Star
13 hours ago
- Indianapolis Star
Divorced and Facing IRS Collection? Clear Start Tax Outlines How Innocent Spouse Relief Could Save You Thousands
Clear Start Tax Explains How Divorced Taxpayers Can Escape IRS Liability for a Former Spouse's Mistakes IRVINE, CA / ACCESS Newswire Divorce can be complicated enough without the added stress of IRS debt. Yet every year, countless divorced Americans are shocked to discover they're on the hook for a former spouse's tax liabilities – often for mistakes they didn't know about. According to Clear Start Tax, a leading national tax resolution firm, the IRS's Innocent Spouse Relief program can offer a powerful – and often overlooked – solution. When Divorce Leaves Taxpayers Facing a Former Spouse's Mistakes Many taxpayers assume that a divorce decree automatically separates their financial obligations. But under joint tax returns, the IRS can pursue either spouse for the full amount owed, including taxes, penalties, and interest. That means years after a divorce, one spouse may face wage garnishment, bank levies, or collection notices for a tax bill they had no role in creating. 'We've worked with clients blindsided by IRS letters years after their divorce,' said the Head of Client Solutions at Clear Start Tax. 'Innocent Spouse Relief can be a lifeline in these cases – but most people don't even realize it exists.' Who Qualifies for Innocent Spouse Relief? Clear Start Tax explains that the IRS looks at several key factors when reviewing Innocent Spouse claims: The tax understatement was due to the other spouse's error (such as unreported income or inflated deductions). The innocent spouse didn't know, and had no reason to know, about the issue at the time. Holding the innocent spouse liable would be unfair or create hardship. The innocent spouse applies within the IRS's filing window (generally two years from first collection notice). Why the Right Approach Is Essential for Approval While the program offers powerful protection, Clear Start Tax emphasizes that success depends on a careful application and thorough documentation. Missing deadlines, submitting incomplete paperwork, or misunderstanding eligibility rules can lead to denial, leaving taxpayers exposed to the full debt. 'Innocent Spouse Relief isn't just a form-it's a carefully built case,' said the Head of Client Solutions at Clear Start Tax. 'We work closely with our clients to present the strongest possible application, so they can move forward without being burdened by a former partner's tax mistakes.' How Clear Start Tax Helps Divorced Taxpayers Regain Control Clear Start Tax offers a hands-on, strategic approach to Innocent Spouse claims and other tax resolution programs: Comprehensive case reviews to assess eligibility and strengthen claims Detailed preparation of IRS applications with supporting evidence Direct IRS communication and negotiation on the client's behalf Post-resolution guidance to maintain compliance and peace of mind About Clear Start Tax Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm's unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry. Need Help With Back Taxes? Click the link below: Contact Information Clear Start Tax Corporate Communications Department seo@ (949) 535-1627 SOURCE: Clear Start Tax View the original press release on ACCESS Newswire
